Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients With Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors

NCT03366103 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT03366103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03366103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients With Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1/2
Overall status
Terminated
Start date
March 20, 2018
Completion date
September 21, 2022
Enrollment
15 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant solid neoplasm, recurrent lung small cell carcinoma, recurrent malignant solid neoplasm, refractory malignant solid neoplasm, stage iii lung small cell carcinoma, by american joint committee on cancer (ajcc) v7, stage iiia lung small cell carcinoma ajcc v7, stage iiib lung small cell carcinoma ajcc v7, stage iv lung small cell carcinoma ajcc v7, unresectable solid neoplasm